Voice outcome after unilateral ELS type III or bilateral type II resections for T1‐T2 glottic carcinoma: Results after 1 year

Background Voice outcome was assessed in patients with extended T1 and limited T2 glottic carcinoma, treated with a unilateral type III or a bilateral type II resection according to the European Laryngological Society (ELS) classification. Methods Objective evaluation (acoustic and aerodynamic param...

Full description

Saved in:
Bibliographic Details
Published inHead & neck Vol. 41; no. 6; pp. 1638 - 1647
Main Authors Loon, Yda, Hendriksma, Martine, Heijnen, Bas J., Kamp, Vivienne A. H., Hakkesteegt, Marieke M., Böhringer, Stefan, Langeveld, Ton P. M., Jong, M. A., Klop, W. Martin C., Baatenburg de Jong, Robert J., Sjögren, Elisabeth V.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.06.2019
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Voice outcome was assessed in patients with extended T1 and limited T2 glottic carcinoma, treated with a unilateral type III or a bilateral type II resection according to the European Laryngological Society (ELS) classification. Methods Objective evaluation (acoustic and aerodynamic parameters), perceptual evaluation (GRBAS), and patients' self‐assessment (voice handicap index [VHI]) were performed before and 1 year after treatment. Results were evaluated according to ELS resection type and the involvement of the anterior commissure. Results The majority of voice parameters in all resection subgroups showed an improvement of the mean score 1 year postoperatively. Grade of dysphonia varied between 1.15 and 1.66 postoperatively and VHI score varied from 23.3 to 24.5. Conclusion Voice outcome after ELS unilateral type III or a bilateral type II resection for extended T1 and limited T2 glottic carcinoma is good with mild to very moderate perceptive dysphonia and low self‐reported voice impairment.
Bibliography:Funding information
ZOLEON, Stichting Oncologie Haaglanden West, Leiden, the Netherlands
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Funding information ZOLEON, Stichting Oncologie Haaglanden West, Leiden, the Netherlands
Yda van Loon and Martine Hendriksma contributed equally to this study.
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.25582